Deciding whom to biopsy

Urologic Oncology: Seminars and Original Investigations

Volumn 28, Issue 5, 2010, Pages 542-545

  Amling, Christopher L ^a   Catalona, William J ^b   Klein, Eric A ^c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Prostate biopsy; Prostate cancer; Prostate specific antigen

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AFRICAN AMERICAN; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; DIAGNOSTIC VALUE; DIGITAL RECTAL EXAMINATION; EARLY DIAGNOSIS; FAMILY HISTORY; GLEASON SCORE; HUMAN; MALE; NOMOGRAM; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; REVIEW;

ADULT; BIOPSY; HUMANS; MALE; MIDDLE AGED; PATIENT SELECTION; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 77956287888     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2010.05.012     Document Type: Review

References (19)

1. Thompson I.M., Pauler D.K., Goodman P.J., et al. Prevalence of prostate cancer among men with a prostate-specific antigen level ≤ 4.0 ng per milliliter. N Engl J Med 2004, 350:2239-2246.
2. Carter H.B., Pearson J.D. PSA velocity for the diagnosis of early prostate cancer. A new concept Urol Clin North Am 1993, 20:665-670.
3. Carter H.B., Ferrucci L., Kettermann A., et al. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Nat Cancer Inst 2006, 98:1521-1527.
4. Loeb S., Roehl K.A., Helfand B.T., et al. Can prostate specific antigen velocity thresholds decrease insignificant prostate cancer detection?. J Urol 2010, 183:112-117.
5. Smith D.S., Catalona W.J. The nature of prostate cancer detected through prostate specific antigen based screening. J Urol 1994, 152:1732-1736.
6. Punglia R.S., D'Amico A.V., Catalona W.J., et al. Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N Engl J Med 2003, 349:335-342.
7. Krumholtz J.S., Carvalhal G.F., Ramos C.G., et al. Prostate-specific antigen cutoff of 2.6 ng/ml for prostate cancer screening is associated with favorable pathologic tumor features. Urol 2002, 60:469-473.
8. Antenor J.V., Roehl K.A., Eggener S.E., et al. Preoperative PSA and progression-free survival after radical prostatectomy for stage T1c disease. Urol 2005, 66:156-160.
9. Lucia M.S., Darke A.K., Goodman P.J., et al. Pathologic characteristics of cancers detected in the Prostate Cancer Prevention Trial: Implications for prostate cancer detection and chemoprevention. Cancer Prev Res 2008, 1:167-173.
10. Makarov D.V., Humphreys E.B., Mangold L.A., et al. Pathological outcomes and biochemical progression in men with T1c prostate cancer undergoing radical prostatectomy with prostate specific antigen 2.6 to 4.0 vs. 4.1 to 6.0 ng/ml. J Urol 2006, 176:554-558.
11. Loeb S., Roehl K.A., Antenor J.V., et al. Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years. Urology 2006, 67:316-320.
12. Carter H.B., Kettermann A., Ferrucci L., et al. Prostate-specific antigen velocity risk count assessment: A new concept for detection of life-threatening prostate cancer during window of curability. Urology 2007, 70:685-690.
13. Catalona W.J., Bartsch G., Rittenhouse H.G., et al. Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen. J Urol 2004, 171:2239-2244.
14. Le B.V., Griffin C.R., Loeb S., et al. [-2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study. J Urol 2010, 183:1355-1359.
15. Jansen F.H., van Schaik R.H., Kurstjens J., et al. Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur Urol 2010 Feb 13, [Epub ahead of print].
16. Thompson I.M., Ankerst D.P., Chi C., et al. Assessing prostate cancer risk: Results from the Prostate Cancer Prevention Trial. J Nat Cancer Inst 2006, 98:529-534.
17. Thompson I.M., Chi C., Ankerst D.P., et al. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Nat Cancer Inst 2006, 98:1128-1133.
18. Eyre S.J., Ankerst D.P., Wei J.T., et al. Validation in a multiple urology practice cohort of the Prostate Cancer Prevention Trial calculator for predicting prostate cancer detection. J Urol 2009, 182:2653-2658.
19. Ankerst D.P., Groskopf J., Day J.R., et al. Predicting prostate cancer risk through incorporation of prostate cancer gene 3. J Urol 2008, 180:1303-1308.